medigraphic.com
ISSN 1561-3003 (Electronic)

2022, Number 1

<< Back Next >>

Rev Cubana Hig Epidemiol 2022; 59 (1)

Population vulnerability to severe COVID-19 according to the data from the national health survey

Venero-Fernández SJ, Suárez-Medina R, Varona PP, Gámez SD, Benítez MM, Corona MB, Hernández SM, Revueltas AM

Language: Spanish
References: 27
Page: 1-21
PDF size: 506.47 Kb.


ABSTRACT

Introduction: New SARS-CoV-2 strains recently detected cause an increase in morbidity and mortality not only in the elderly. Identifying the vulnerable population is a challenge.
Objective: To estimate the prevalence of adults vulnerable to severe COVID-19 and its associated sociodemographic factors.
vMethods: An observational cross-sectional analytic study using data from the 2018-2020 National Health Survey. It included 13 684 individuals aged 19 years and over. The structured questionnaire included information on the sociodemographic variables, personal and family pathological antecedents, and records of blood pressure and biochemistry tests, among others. Vulnerability to severe COVID-19 was developed based on the proposal from the CDC Atlanta, USA and it was the dependable variable.
Results: The prevalence of adults vulnerable to severe COVID-19 in the country was 68.3%. At higher risk are the elderly (86.5%), non-white individuals, and those who perceived themselves as having poor living conditions. For the elderly, being male was a protective factor, while living in the western region of the country was a risk factor. High blood pressure (39.4%), smoking (22.2%), obesity (16.6%) and chronic respiratory diseases (10.6%) were the most frequent health problems.
Conclusions: Vulnerability to severe COVID-19 in the Cuban adult population is high; consequently, it is considered a serious health problem. Non-modifiable factors are positively associated with vulnerability: being an older adult, female, non-white skin color, and suffering from hypertension; while “poor” living conditions is the only modifiable factor.


REFERENCES

  1. World Health Organization. Director -General's remarks at the media briefing on 2019- nCoV on 10 February 2020. Geneva: WHO; 2020 [acceso 03/09/2021]. Disponible en: Disponible en: https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-10-february-2020 1.

  2. Centers for Disease Control and Prevention. What you can do if you are at higher risk of severe illness from COVID-19. Atlanta: CDC; 2019 [acceso 03/09/2021]. Disponible en: Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/downloads/COVID19-What-You-Can-Do-High-Risk.pdf 2.

  3. Adam SH, Park MJ, Schaud JP, Brindis CD, Irwin ChE. Medical Vulnerability of young adults to severe COVID-19 Illness-Data From the National Health Interview Survey. J Adolesc Health 2020;67(3):362-8. DOI: https://doi.org/10.1016/j.jadohealth.2020.06.0253.

  4. Venero-Fernández SJ, Más Gómez M, Cuellar Luna L, de Armas Águila Y, Suárez Medina R, Pérez González DR, et al. Características epidemiológicas de la COVID-19 en La Habana, epicentro de Cuba. Rev. Cubana Hig Epidemiol 2021 [acceso 25/08/2021];58:e1025. Disponible en: http://www.revepidemiologia.sld.cu/index.php/hie/article/view/10254.

  5. Ministerio de Salud Pública. Anuario Estadístico de Salud 2019.La Habana: MINSAP; 2020. [acceso 25/08/2021]; Disponible en: Disponible en: https://files.sld.cu/bvscuba/files/2020/05/Anuario-Electr%c3%b3nico-Espa%c3%b1ol-2019-ed-2020.pdf 5.

  6. Bonet Gorbea M, Varona Pérez P. III Encuesta Nacional de Factores de Riesgo, Cuba, 2010-2011. La Habana: Editorial Ciencias Médicas; 2014. [acceso 23/08/2021]. Disponible en: Disponible en: http://www.bvs.sld.cu/libros/encuesta_nacional_riesgo/indice_p.htm 6.

  7. Wyper GMA, Assunção R, Cuschieri S, Devleesschauwer B, Fletcher E, Haagsma JA, et al. Population vulnerability to COVID-19 in Europe: a burden of disease analysis. Arch Public Health 2020;78(47):1-8. DOI: https://doi.org/10.1186/s13690-020-00433-y7.

  8. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. How many are at increased risk of severe COVID-19 disease? Rapid global, regional and national estimates for 2020. MedRxiv Preprint. BMJ Yale. 2020:1-28. DOI: https://doi.org/10.1101/2020.04.18.200647748.

  9. Zhang N, Xie T, Ning W, He R, Zhu B, Mao Y. The Severity of COVID-19 and its determinants: A Systematic Review and Meta-Analysis in China. Sustainability. 2021;13(9):5305. DOI: https://doi.org/10.3390/su130953059.

  10. Alfonso AC. La población cubana ante factores de riesgo para la salud. Un análisis por color de la piel y provincias 2001- parte urbana [tesis]. La Habana: CEDEM, Universidad de La Habana; 2009. [ Links ]

  11. Albizu-Campos Espiñeira JC, Cabrera Marrero F. La mortalidad en Cuba según el color de la piel. Rev Nov Poblac. 2014 [acceso 09/02/2022];10(20):31-61. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-40782014000200004&lng=es&tlng=es11.

  12. Zabala Argüelles MC. Desigualdades por color de la piel e interseccionalidad: análisis del contexto cubano 2008-2018. FLACSO-Cuba. La Habana: Publicaciones Acuario, Centro Félix Varela; 2020 [acceso 9/2/2022]. Disponible en: Disponible en: http://biblioteca.clacso.edu.ar/Cuba/flacso-cu/20201103111644/5-Desigualdades-color.pdf 12.

  13. October KR, Petersen LR, Adebiyi B, Rich E, Roman NV. COVID-19 Daily Realities for Families: A South African Sample. Int J Environ Res Public Health. 2022;19(1):221. DOI: https://doi.org/10.3390/ijerph1901022113.

  14. Elhusseina A, Anderson A, Bancks MP, Coday M, Knowler WC, Petersf A; the Look AHEAD Research Group; et al. Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study. Lancet Reg Health Am. 2022:6. DOI: https://doi.org/10.1016/j.lana.2021.10011114.

  15. Marshall WF. Infección con coronavirus por raza: ¿qué hay de fondo tras las desigualdades en la salud? Respuetas. Rochester,Minnesota: Mayo Clinic; 2020. [acceso 09/02/2022]. Disponible en: Disponible en: https://www.mayoclinic.org/es-es/diseases-conditions/coronavirus/expert-answers/coronavirus-infection-by-race/faq-20488802 15.

  16. Farsalinos K, Bagos PG, Giannouchos T, Niaura R, Barbouni A, Poulas K. Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication. Harm Reduct. J. 2021;18(9).1-9. DOI: https://doi.org/10.1186/s12954-020-00437-516.

  17. Roblejo Balbuena H, Benítez Cordero Y, Álvarez Gavilán Y, Bravo Ramírez M, Pereira Roche N, García Gómez D, et al. Características clínico-epidemiológicas de pacientes cubanos residentes en La Habana afectados por la COVID-19. Rev Cubana Invest Bioméd. 2021 [acceso 09/02/2022];40(2):e1566. Disponible en: http://www.revibiomedica.sld.cu/index.php/ibi/article/view/156617.

  18. Matsushita K, Ding N, Kou M, Hu X, Chen M, Gao Y, et al. The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. Global Heart. 2020;15(1):64. DOI: https://doi.org/10.5334/gh.81418.

  19. Mubarik S, Liu X, Eshak ES, Liu K, Liu Q, Wang F, et al. The Association of Hypertension with the Severity of and Mortality From the COVID-19 in the Early Stage of the Epidemic in Wuhan, China: A Multicenter Retrospective Cohort Study. Front. Med. 2021;8:623608. DOI: https://doi.org/10.3389/fmed.2021.62360819.

  20. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS Coronavirus. J Virol. 2020;94(7). DOI: https://doi.org/10.1128/JVI.00127-2020.

  21. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80. DOI: https://doi.org/10.1016/j.cell.2020.02.05221.

  22. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 2020;8(4):E21. DOI: https://doi.org/10.1016/S2213-2600(20)30116-822.

  23. European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. España: Representación de la ESC; 2020. [acceso 23/09/2021]. Disponible en: Disponible en: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang 23.

  24. Ng WH, Tipih T, Makoah NA, Vermeulen J-G, Goedhals D, Sempa JB, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. mBio. 2021;12(1):e03647-20. DOI: https://doi.org/10.1128/mBio.03647-20 mBio.24.

  25. Yang J, Ma Z, Lei Y. A meta-analysis of the association between obesity and COVID-19. Epidemiol. Infect. 2021;149(11):1-14. DOI: https://doi.org/10.1017/s095026882000302725.

  26. Lin L, Chen Z, Ding T, Liu H, Zhou F, Huang X, et al. Newly-Diagnosed Diabetes and Sustained Hyperglycemia are Associated with Poorer Outcomes in COVID-19 Inpatients Without Pre-Existing Diabetes. Diabetes Metab Syndr Obes. 2021;14:4469-82. DOI: https://doi.org/10.2147/DMSO.S33281926.

  27. Dadhwal R, Sharma M, Surani S. Restrictive Lung Disease in Patients with Subclinical Coronavirus Infection: Are We Bracing Ourselves for Devastating Sequelae? Cureus. 2021;13(1):e12501. DOI: https://doi.org/10.7759/cureus.1250127.




2020     |     www.medigraphic.com